• News
  • SAN DIEGO
  • BioTech

International Stem Cell Corp. revenues up 35%

International Stem Cell Corp. (OTC: ISCO), a Carlsbad-based biotechnology company developing novel stem cell-based therapies and biomedical products, Tuesday provided a business update and announced fourth quarter and year-end financial results for the year ended Dec. 31, 2013.

The company earned $6.15 million in revenue for the year ended Dec. 31, an increase of 35 percent compared to 2012. Lifeline Skin Care sales were up 47 percent and Lifeline Cell Technology sales increased 24 percent. Its gross margin improved to 73 percent in 2013 from 72 percent in 2012.

International Stem Cell Corp.'s net cash provided by financing activities was $8.12 million for the year ended Dec. 31, 2013, compared to $6.79 million in 2012.

The company also said it continues to execute on its plan to develop human parthenogenetic neural stem cells (hPNSC) as a clinical product candidate for the treatment of Parkinson's disease (PD).

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

International Stem Cell Corp.

Company Website

5950 Priestly Dr.
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISCO
3.94
  0.14  
+ 3.68%
9,315,000
18.15
1.25

International Stem Cell Corp. Executive(s):

Andrey Semechkin

  • Chief Executive Officer